The cost of care for children hospitalized with respiratory syncytial virus (RSV) associated lower respiratory infection in Kenya.
Humans
Kenya
/ epidemiology
Respiratory Syncytial Virus Infections
/ economics
Child, Preschool
Infant
Female
Male
Hospitalization
/ economics
Respiratory Tract Infections
/ economics
Health Care Costs
/ statistics & numerical data
Cost of Illness
Surveys and Questionnaires
Respiratory Syncytial Virus, Human
Health Expenditures
/ statistics & numerical data
Infant, Newborn
Cost
Health System
Hospitalization
Households
Respiratory syncytial virus
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
04 Sep 2024
04 Sep 2024
Historique:
received:
06
12
2023
accepted:
26
08
2024
medline:
5
9
2024
pubmed:
5
9
2024
entrez:
4
9
2024
Statut:
epublish
Résumé
Respiratory syncytial virus (RSV) is one of the main causes of hospitalization for lower respiratory tract infection in children under five years of age globally. Maternal vaccines and monoclonal antibodies for RSV prevention among infants are approved for use in high income countries. However, data are limited on the economic burden of RSV disease from low- and middle-income countries (LMIC) to inform decision making on prioritization and introduction of such interventions. This study aimed to estimate household and health system costs associated with childhood RSV in Kenya. A structured questionnaire was administered to caregivers of children aged < 5 years admitted to referral hospitals in Kilifi (coastal Kenya) and Siaya (western Kenya) with symptoms of acute lower respiratory tract infection (LRTI) during the 2019-2021 RSV seasons. These children had been enrolled in ongoing in-patient surveillance for respiratory viruses. Household expenditures on direct and indirect medical costs were collected 10 days prior to, during, and two weeks post hospitalization. Aggregated health system costs were acquired from the hospital administration and were included to calculate the cost per episode of hospitalized RSV illness. We enrolled a total of 241 and 184 participants from Kilifi and Siaya hospitals, respectively. Out of these, 79 (32.9%) in Kilifi and 21(11.4%) in Siaya, tested positive for RSV infection. The total (health system and household) mean costs per episode of severe RSV illness was USD 329 (95% confidence interval (95% CI): 251-408 ) in Kilifi and USD 527 (95% CI: 405- 649) in Siaya. Household costs were USD 67 (95% CI: 54-80) and USD 172 (95% CI: 131- 214) in Kilifi and Siaya, respectively. Mean direct medical costs to the household during hospitalization were USD 11 (95% CI: 10-12) and USD 67 (95% CI: 51-83) among Kilifi and Siaya participants, respectively. Observed costs were lower in Kilifi due to differences in healthcare administration. RSV-associated disease among young children leads to a substantial economic burden to both families and the health system in Kenya. This burden may differ between Counties in Kenya and similar multi-site studies are advised to support cost-effectiveness analyses.
Sections du résumé
BACKGROUND
BACKGROUND
Respiratory syncytial virus (RSV) is one of the main causes of hospitalization for lower respiratory tract infection in children under five years of age globally. Maternal vaccines and monoclonal antibodies for RSV prevention among infants are approved for use in high income countries. However, data are limited on the economic burden of RSV disease from low- and middle-income countries (LMIC) to inform decision making on prioritization and introduction of such interventions. This study aimed to estimate household and health system costs associated with childhood RSV in Kenya.
METHODS
METHODS
A structured questionnaire was administered to caregivers of children aged < 5 years admitted to referral hospitals in Kilifi (coastal Kenya) and Siaya (western Kenya) with symptoms of acute lower respiratory tract infection (LRTI) during the 2019-2021 RSV seasons. These children had been enrolled in ongoing in-patient surveillance for respiratory viruses. Household expenditures on direct and indirect medical costs were collected 10 days prior to, during, and two weeks post hospitalization. Aggregated health system costs were acquired from the hospital administration and were included to calculate the cost per episode of hospitalized RSV illness.
RESULTS
RESULTS
We enrolled a total of 241 and 184 participants from Kilifi and Siaya hospitals, respectively. Out of these, 79 (32.9%) in Kilifi and 21(11.4%) in Siaya, tested positive for RSV infection. The total (health system and household) mean costs per episode of severe RSV illness was USD 329 (95% confidence interval (95% CI): 251-408 ) in Kilifi and USD 527 (95% CI: 405- 649) in Siaya. Household costs were USD 67 (95% CI: 54-80) and USD 172 (95% CI: 131- 214) in Kilifi and Siaya, respectively. Mean direct medical costs to the household during hospitalization were USD 11 (95% CI: 10-12) and USD 67 (95% CI: 51-83) among Kilifi and Siaya participants, respectively. Observed costs were lower in Kilifi due to differences in healthcare administration.
CONCLUSIONS
CONCLUSIONS
RSV-associated disease among young children leads to a substantial economic burden to both families and the health system in Kenya. This burden may differ between Counties in Kenya and similar multi-site studies are advised to support cost-effectiveness analyses.
Identifiants
pubmed: 39232690
doi: 10.1186/s12889-024-19875-y
pii: 10.1186/s12889-024-19875-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2410Subventions
Organisme : PATH
ID : GAT. 1890-01665713
Organisme : PATH
ID : GAT. 1890-01665713
Organisme : PATH
ID : GAT. 1890-01665713
Organisme : PATH
ID : GAT. 1890-01665713
Organisme : PATH
ID : GAT. 1890-01665713
Organisme : PATH
ID : GAT. 1890-01665713
Organisme : PATH
ID : GAT. 1890-01665713
Organisme : PATH
ID : GAT. 1890-01665713
Organisme : PATH
ID : GAT. 1890-01665713
Organisme : PATH
ID : GAT. 1890-01665713
Organisme : PATH
ID : GAT. 1890-01665713
Organisme : PATH
ID : GAT. 1890-01665713
Organisme : PATH
ID : GAT. 1890-01665713
Organisme : PATH
ID : GAT. 1890-01665713
Organisme : PATH
ID : GAT. 1890-01665713
Organisme : PATH
ID : GAT. 1890-01665713
Organisme : PATH
ID : GAT. 1890-01665713
Organisme : Wellcome Trust
ID : 102975
Pays : United Kingdom
Informations de copyright
© 2024. The Author(s).
Références
Li Y, Johnson EK, Shi T, Campbell H, Chaves SS, Commaille-Chapus C, Dighero I, James SL, Mahe C, Ooi Y, et al. National burden estimates of hospitalisations for acute lower respiratory infections due to respiratory syncytial virus in young children in 2019 among 58 countries: a modelling study. Lancet Respir Med. 2021;9(2):175–85.
doi: 10.1016/S2213-2600(20)30322-2
pubmed: 32971018
PERCH. Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: the PERCH multi-country case-control study. Lancet. 2019;394(10200):757–79.
doi: 10.1016/S0140-6736(19)30721-4
Shi T, McAllister DA, O’Brien KL, Simoes EAF, Madhi SA, Gessner BD, Polack FP, Balsells E, Acacio S, Aguayo C, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017;390(10098):946–58.
doi: 10.1016/S0140-6736(17)30938-8
pubmed: 28689664
pmcid: 5592248
Li Y, Wang X, Blau DM, Caballero MT, Feikin DR, Gill CJ, Madhi SA, Omer SB, Simoes EAF, Campbell H, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022;399(10340):2047–64.
doi: 10.1016/S0140-6736(22)00478-0
pubmed: 35598608
pmcid: 7613574
Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, O’Brien KL, Roca A, Wright PF, Bruce N, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375(9725):1545–55.
doi: 10.1016/S0140-6736(10)60206-1
pubmed: 20399493
pmcid: 2864404
Mazur NI, Lowensteyn YN, Willemsen JE, Gill CJ, Forman L, Mwananyanda LM, Blau DM, Breiman RF, Madhi SA, Mahtab S, et al. Global respiratory Syncytial Virus-Related Infant Community deaths. Clin Infect Dis. 2021;73(Suppl_3):S229–37.
doi: 10.1093/cid/ciab528
pubmed: 34472576
pmcid: 8411255
Nokes DJ, Ngama MJ, Bett A, Abwao J, Munywoki P, English M, Scott JAG, Cane PA, Medley GF. Incidence and severity of respiratory syncytial virus pneumonia in rural Kenyan children identified through hospital surveillance. Clin Infect Dis. 2009;49(9):1341–9.
doi: 10.1086/606055
pubmed: 19788358
PATH. RSV vaccine and mAb snapshot. https://www.pathorg/resources/rsv-vaccine-and-mab-snapshot (updated 21st September 2023) 2023.
Kampmann B, Madhi SA, Munjal I, Simoes EAF, Pahud BA, Llapur C, Baker J, Perez Marc G, Radley D, Shittu E, et al. Bivalent Prefusion F vaccine in pregnancy to prevent RSV illness in infants. N Engl J Med. 2023;388(16):1451–64.
doi: 10.1056/NEJMoa2216480
pubmed: 37018474
Hammitt LL, Dagan R, Yuan Y, Baca Cots M, Bosheva M, Madhi SA, Muller WJ, Zar HJ, Brooks D, Grenham A, et al. Nirsevimab for Prevention of RSV in healthy late-preterm and term infants. N Engl J Med. 2022;386(9):837–46.
doi: 10.1056/NEJMoa2110275
pubmed: 35235726
Cetinkaya M, Oral TK, Karatekin S, Cebeci B, Babayigit A, Yesil Y. Efficacy of palivizumab prophylaxis on the frequency of RSV-associated lower respiratory tract infections in preterm infants: determination of the ideal target population for prophylaxis. Eur J Clin Microbiol Infect Dis. 2017;36(9):1629–34.
doi: 10.1007/s10096-017-2976-x
pubmed: 28391538
Wittenauer R, Pecenka C, Baral R. Cost of childhood RSV management and cost-effectiveness of RSV interventions: a systematic review from a low- and middle-income country perspective. BMC Med. 2023;21(1):121.
doi: 10.1186/s12916-023-02792-z
pubmed: 37004038
pmcid: 10067246
Dvorkin J, Sosa E, Vodicka E, Baral R, Sancilio A, Duenas K, Rodriguez A, Rojas-Roque C, Carruitero PB, Polack FP, et al. Cost of illness due to respiratory syncytial virus acute lower respiratory tract infection among infants hospitalized in Argentina. BMC Public Health. 2024;24(1):427.
doi: 10.1186/s12889-024-17878-3
pubmed: 38336643
pmcid: 10858556
Do LAH, Vodicka E, Nguyen A, Le TNK, Nguyen TTH, Thai QT, Pham VQ, Pham TU, Nguyen TN, Mulholland K, et al. Estimating the economic burden of respiratory syncytial virus infections in infants in Vietnam: a cohort study. BMC Infect Dis. 2023;23(1):73.
doi: 10.1186/s12879-023-08024-2
pubmed: 36747128
pmcid: 9901829
Baral R, Mambule I, Vodicka E, French N, Everett D, Pecenka C, Bar-Zeev N. Estimating the economic impact of respiratory Syncytial Virus and other Acute Respiratory infections among infants receiving care at a Referral Hospital in Malawi. J Pediatr Infect Dis Soc. 2020;9(6):738–45.
doi: 10.1093/jpids/piaa157
Ayieko P, Akumu AO, Griffiths UK, English M. The economic burden of inpatient paediatric care in Kenya: household and provider costs for treatment of pneumonia, malaria and meningitis. Cost Eff Resour Alloc. 2009;7:3.
doi: 10.1186/1478-7547-7-3
pubmed: 19161598
pmcid: 2640355
Emukule GO, Ndegwa LK, Washington ML, Paget JW, Duque J, Chaves SS, Atieno NA, Wamburu K, Ndigirigi IW, Muthoka M et al. The cost of influenza-associated hospitalizations and outpatient visits in Kenya. BMC Public Health 2019.
Kenya. Kenya’s constitution of 2010. 2010:56–62.
Kairu A, Orangi S, Mbuthia B, Ondera J, Ravishankar N, Barasa E. Examining health facility financing in Kenya in the context of devolution. BMC Health Serv Res. 2021;21(1):1086.
doi: 10.1186/s12913-021-07123-7
pubmed: 34645443
pmcid: 8515645
Nyawanda BO, Murunga N, Otieno NA, Bigogo G, Nyiro JU, Vodicka E, Bulterys M, Nokes DJ, Munywoki PK, Emukule GO. Estimates of the national burden of respiratory syncytial virus in Kenyan children aged under 5 years, 2010–2018. BMC Med. 2023;21(1):122.
doi: 10.1186/s12916-023-02787-w
pubmed: 37004034
pmcid: 10067313
Organization WH. Guidelines for estimating the economic burden of diarrhoeal disease, with focus on assessing the costs of rotavirus diarrhoea. World Health Organization; 2005.
Gunson RN, Collins TC, Carman WF. Real-time RT-PCR detection of 12 respiratory viral infections in four triplex reactions. J Clin Virol. 2005;33(4):341–4.
doi: 10.1016/j.jcv.2004.11.025
pubmed: 15927526
pmcid: 7108440
Hammitt LL, Kazungu S, Welch S, Bett A, Onyango CO, Gunson RN, Scott JA, Nokes DJ. Added value of an oropharyngeal swab in detection of viruses in children hospitalized with lower respiratory tract infection. J Clin Microbiol. 2011;49(6):2318–20.
doi: 10.1128/JCM.02605-10
pubmed: 21490188
pmcid: 3122752
Nyawanda BO, Otieno NA, Otieno MO, Emukule GO, Bigogo G, Onyango CO, Lidechi S, Nyaundi J, Langley GE, Widdowson MA et al. The impact of maternal HIV infection on the burden of respiratory syncytial virus among pregnant women and their infants, western Kenya. J Infect Dis 2020.
Nyiro JU, Nyawanda B, Mutunga M, Murunga N, Bigogo G, Otieno N, Lidechi S, Mazoya B, Jit M, Cohen C et al. Replication Data for: The cost of care for children hospitalized with respiratory syncytial virus (RSV) associated lower respiratory tract infection (LRTI) in Kenya, https://doi.org/10.7910/DVN/XIYHXF Havard dataverse 2022, V1,(UNF:6:jeXpAG/EnOsi4HCYQx9d5g==[fileUNF]).
Hendrix N, Bar-Zeev N, Atherly D, Chikafa J, Mvula H, Wachepa R, Crampin AC, Mhango T, Mwansambo C, Heyderman RS, et al. The economic impact of childhood acute gastroenteritis on Malawian families and the healthcare system. BMJ open. 2017;7(9):e017347.
doi: 10.1136/bmjopen-2017-017347
pubmed: 28871025
pmcid: 5589001
Turner HC, Lauer JA, Tran BX, Teerawattananon Y, Jit M. Adjusting for Inflation and Currency Changes within Health Economic Studies. Value Health. 2019;22(9):1026–32.
doi: 10.1016/j.jval.2019.03.021
pubmed: 31511179
Koltai M, Moyes J, Nyawanda B, Nyiro J, Munywoki PK, Tempia S, Li X, Antillon M, Bilcke J, Flasche S, et al. Estimating the cost-effectiveness of maternal vaccination and monoclonal antibodies for respiratory syncytial virus in Kenya and South Africa. BMC Med. 2023;21(1):120.
doi: 10.1186/s12916-023-02806-w
pubmed: 37004062
pmcid: 10064962
Mwenda N, Nduati R, Kosgei M, Kerich G. What drives outpatient care costs in Kenya? An analysis with generalized estimating equations. Front Public Health. 2021;9:648465.
doi: 10.3389/fpubh.2021.648465
pubmed: 34631637
pmcid: 8492944
Berkley JA, Munywoki P, Ngama M, Kazungu S, Abwao J, Bett A, Lassauniere R, Kresfelder T, Cane PA, Venter M, et al. Viral etiology of severe pneumonia among Kenyan infants and children. JAMA. 2010;303(20):2051–7.
doi: 10.1001/jama.2010.675
pubmed: 20501927
pmcid: 2968755
Bhuiyan MU, Luby SP, Alamgir NI, Homaira N, Sturm-Ramirez K, Gurley ES, Abedin J, Zaman RU, Alamgir A, Rahman M, et al. Costs of hospitalization with respiratory syncytial virus illness among children aged < 5 years and the financial impact on households in Bangladesh, 2010. J Glob Health. 2017;7(1):010412.
pubmed: 28702175
pmcid: 5502704
Organization WH. Acute respiratory infections in children: case management in small hospitals in developing countries, a manual for doctors and other senior health workers. WHO 1990.
Thorburn K, Harigopal S, Reddy V, Taylor N, van Saene HK. High incidence of pulmonary bacterial co-infection in children with severe respiratory syncytial virus (RSV) bronchiolitis. Thorax. 2006;61(7):611–5.
doi: 10.1136/thx.2005.048397
pubmed: 16537670
pmcid: 2104657
Hanada S, Pirzadeh M, Carver KY, Deng JC. Respiratory viral infection-Induced Microbiome alterations and secondary bacterial pneumonia. Front Immunol. 2018;9:2640.
doi: 10.3389/fimmu.2018.02640
pubmed: 30505304
pmcid: 6250824